Gemina Laboratories Ltd. (CSE:GLAB)
Canada
· Delayed Price · Currency is CAD 0.220
+0.040 (22.22%)
Dec 5, 2025, 3:58 PM EST
Gemina Laboratories Company Description
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada.
The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test.
It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Gemina Laboratories Ltd.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Robert Greene |
Contact Details
Address: 3600 Gilmore Way Burnaby, British Columbia V5G 4W8 Canada | |
| Website | geminalabs.com |
Stock Details
| Ticker Symbol | GLAB |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | February - January |
| Reporting Currency | CAD |
| ISIN Number | CA3686501071 |
| SIC Code | 6722 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Crandall Greene | Chief Executive Officer and Director |
| Dr. Christine Buerki Ph.D. | Head of Research and Development |